The Belgian pharmaceutical company UCB announced on Monday that it will sell its neurology and allergy business in China to the investment companies CBC from Singapore and Mubadala from Abu Dhabi for 680 million dollars. The deal includes UCB’s neurology portfolio, which includes drugs such as Keppra, Vimpat, and Neupro, as well as the anti-allergy drugs Zyrtec and Xyzal.